Home >> Research Area >>Others>>Others>> Triamcinolone Acetonide

Triamcinolone Acetonide

Antiinflammatory steroid CAS# 76-25-5

Triamcinolone Acetonide

Catalog No. BCC3871----Order now to get a substantial discount!

Product Name & Size Price Stock
Triamcinolone Acetonide: 5mg $17 In Stock
Triamcinolone Acetonide: 10mg Please Inquire In Stock
Triamcinolone Acetonide: 20mg Please Inquire Please Inquire
Triamcinolone Acetonide: 50mg Please Inquire Please Inquire
Triamcinolone Acetonide: 100mg Please Inquire Please Inquire
Triamcinolone Acetonide: 200mg Please Inquire Please Inquire
Triamcinolone Acetonide: 500mg Please Inquire Please Inquire
Triamcinolone Acetonide: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Triamcinolone Acetonide

Number of papers citing our products

Chemical structure

Triamcinolone Acetonide

3D structure

Chemical Properties of Triamcinolone Acetonide

Cas No. 76-25-5 SDF Download SDF
PubChem ID 6436 Appearance Powder
Formula C24H31FO6 M.Wt 434.5
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 50 mg/mL (115.07 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
SMILES CC1(OC2CC3C4CCC5=CC(=O)C=CC5(C4(C(CC3(C2(O1)C(=O)CO)C)O)F)C)C
Standard InChIKey YNDXUCZADRHECN-JNQJZLCISA-N
Standard InChI InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Triamcinolone Acetonide

DescriptionTriamcinolone Acetonide is a more potent type of triamcinolone, being about 8 times as effective as prednisone. Target: Glucocorticoid Receptor Triamcinolone acetonide is a synthetic corticosteroid used to treat various skin conditions, to relieve the discomfort of mouth sores, and in nasal spray form, to treat allergic rhinitis. It is a more potent derivative of triamcinolone, and is about 8 times as potent as prednisone [1].

References:
[1]. http://en.wikipedia.org/wiki/Triamcinolone_acetonide

Triamcinolone Acetonide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Triamcinolone Acetonide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Triamcinolone Acetonide

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.3015 mL 11.5075 mL 23.015 mL 46.0299 mL 57.5374 mL
5 mM 0.4603 mL 2.3015 mL 4.603 mL 9.206 mL 11.5075 mL
10 mM 0.2301 mL 1.1507 mL 2.3015 mL 4.603 mL 5.7537 mL
50 mM 0.046 mL 0.2301 mL 0.4603 mL 0.9206 mL 1.1507 mL
100 mM 0.023 mL 0.1151 mL 0.2301 mL 0.4603 mL 0.5754 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Triamcinolone Acetonide

Triamcinolone acetonide is an antiinflammatory steroid that inhibits the IgE-dependent release of histamine. This is done by human basophils and the growth of NEL-M1 human melanoma cells.

Featured Products
New Products
 

References on Triamcinolone Acetonide

A Prospective Randomized Trial of the Efficacy of Fibrin Glue, Triamcinolone Acetonide, and Quilting Sutures in Seroma Prevention after Latissimus Dorsi Breast Reconstruction.[Pubmed:28350654]

Plast Reconstr Surg. 2017 Apr;139(4):854e-863e.

BACKGROUND: Donor-site seroma is the most common complication following latissimus dorsi flap breast reconstruction. Various agents and techniques have attempted to minimize seroma formation. The purpose of this study was to compare the efficacy of different products and quilting sutures at seroma prevention. METHODS: This is a single-center, double-blinded, randomized, controlled trial of a consecutive series of breast cancer patients (n = 96) undergoing latissimus dorsi flap reconstruction performed by a single surgeon. Patients were randomized to receive (1) fibrin glue (Tisseel) (n = 23), (2) Triamcinolone Acetonide (n = 26), or (3) normal saline (control) (n = 27) sprayed into the donor site. The fourth arm included donor-site quilting sutures (n = 20). Outcomes included seroma, drain output, and days to last drain removal. Drain removal was standardized at less than 30 cc/day. RESULTS: All groups were matched evenly without differences in risk, procedures, or complications. The overall seroma rate was 31.3 percent (n = 30). The quilting group had significantly less drainage for weeks 1 (p = 0.006) and 2 (p = 0.050) postoperatively. Quilting statistically reduced the incidence of seromas to 5.0 percent (n = 1; p = 0.038) compared with other groups (control, 34.5 percent; fibrin, 27.6 percent; and triamcinolone, 37.6 percent). Drains were removed 10 days earlier with quilting (control, 35.5 days; fibrin, 39.5 days; triamcinolone, 37.4 days; and quilting, 25.8 days; p = 0.001). The incidence of all other complications was similar between groups. CONCLUSION: The use of quilting donor sites significantly decreases the incidence of donor-site seromas and leads to earlier drain removal following latissimus dorsi flap reconstruction and maintains a low complication profile. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

Mechanisms of in vivo release of triamcinolone acetonide from PLGA microspheres.[Pubmed:28342981]

J Control Release. 2017 Jun 28;256:19-25.

Little is known about the underlying effects controlling in vitro-in vivo correlations (IVIVCs) for biodegradable controlled release microspheres. Most reports of IVIVCs that exist are empirical in nature, typically based on a mathematical relationship between in vitro and in vivo drug release, with the latter often estimated by deconvolution of pharmacokinetic data. In order to improve the ability of in vitro release tests to predict microsphere behavior in vivo and develop more meaningful IVIVCs, the in vivo release mechanisms need to be characterized. Here, two poly(lactic-co-glycolic acid) (PLGA) microsphere formulations encapsulating the model steroid Triamcinolone Acetonide (Tr-A) were implanted subcutaneously in rats by using a validated cage model, allowing for free fluid and cellular exchange and microsphere retrieval during release. Release kinetics, as well as mechanistic indicators of release such as hydrolysis and mass loss, was measured by direct analysis of the recovered microspheres. Release of Tr-A from both formulations was greatly accelerated in vivo compared to in vitro using agitated phosphate buffered saline +0.02% Tween 80 pH7.4, including rate of PLGA hydrolysis, mass loss and water uptake. Both microsphere formulations exhibited erosion-controlled release in vitro, indicated by similar polymer mass loss kinetics, but only one of the formulations (low molecular weight, free acid terminated) exhibited the same mechanism in vivo. The in vivo release of Tr-A from microspheres made of a higher molecular weight, ester end-capped PLGA displayed an osmotically induced/pore diffusion mechanism based on confocal micrographs of percolating pores in the polymer, not previously observed in vitro. This research indicates the need to fully understand the in vivo environment and how it causes drug release from biodegradable microspheres. This understanding can then be applied to develop in vitro release tests which better mimic this environment and cause drug release by the relevant mechanistic processes, ultimately leading to the development of mechanism based IVIVCs.

Vessel diameter study: intravitreal vs posterior subtenon triamcinolone acetonide injection for diabetic macular edema.[Pubmed:28338665]

Eye (Lond). 2017 Aug;31(8):1155-1162.

PurposeTo detect and compare the vessel diameter effect of intravitreal vs subtenon injection of triamcinolone for diabetic macular edema (DME).MethodsSixty patients with DME who underwent triamcinolone injection either intravitreally (N=30) or under the tenon capsule (N=30) were included. Non-injected fellow eyes served as control. The main outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and artery-vein ratio (AVR).ResultsIn the intravitreal group, pre-injection mean CRAE (147.07 mu) decreased to 141.03 mu at 1 week and to 139.43 mu at 1 month (P<0.001) while baseline CRVE (209.61 mu) decreased initially to 198.85 mu at 1 week then to 198.49 mu at 1 month (P<0.001). In the subtenon group, pre-injection CRAE (152.18 mu) decreased to 149.49 mu at 1 week and to 147.47 mu at 1 month (P=0.017), while baseline CRVE (215.60 mu) decreased initially to 208.69 mu at 1 week then to 207.25 mu at 1 month (P=0.003). Pre-injection AVR values did not change at 1 week and at 1 month in both injection groups (P=0.66 and P=0.196, respectively). In the control group, none of the 3 parameters changed throughout the study period compared to the baseline (P>0.28).ConclusionIn eyes with DME, both intravitreal and subtenon triamcinolone injection led to a significant constriction of retinal arteries and veins.

Description

Triamcinolone acetonide is a more potent type of triamcinolone, being about 8 times as effective as prednisone.

Keywords:

Triamcinolone Acetonide,76-25-5,Natural Products,Others, buy Triamcinolone Acetonide , Triamcinolone Acetonide supplier , purchase Triamcinolone Acetonide , Triamcinolone Acetonide cost , Triamcinolone Acetonide manufacturer , order Triamcinolone Acetonide , high purity Triamcinolone Acetonide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: